The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003
Increased expression of phosphodiesterase 4 (PDE4) A, B and D in alveolar macrophages from chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2011 - Macrophages and neutrophils in chronic lung disease Year: 2011
Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: results of a 6-month trial Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001
Roflumilast, a new orally active phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 374s Year: 2002
Effects of phosphodiesterase 3/4 inhibition on matrixmetalloproteinases 2 and 9 in chronic experimental pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 435s Year: 2004
The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD Source: Eur Respir J, 52 (5) 1801074; 10.1183/13993003.01074-2018 Year: 2018
Airway remodelling augmented in patients with asthma COPD overlap (ACO) compared to asthma and COPD. Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021
Adenosine 5’ – triphosphate (ATP) and adenosine 5' – monophosphate (AMP) challenge testing in current smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003
The expression of MMP2, 9 and TIMP1 mRNA in bronchoalveolar cells of patients with chronic obstructive pulmonary disease (COPD) and bronchial asthma Source: Annual Congress 2009 - New results in molecular pathology and functional genomics of non-neoplastic lung diseases Year: 2009
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD Source: Eur Respir J 2009; 33: 1039-1044 Year: 2009
Study on levels of high sensitivity C reactive protein in asthmatic patients during exacerbation and remission and its correlation with pulmonary function Source: Annual Congress 2007 - Mechanisms of airway inflammation Year: 2007
Cilomilast decreases exacerbations and maintains lung function in patients with poorly reversible COPD Source: Eur Respir J 2004; 24: Suppl. 48, 88s Year: 2004
The effect of leukotrienes receptor antagonists on lung function, exercise tolerance and incidence of exacerbations in patients with stable, moderate COPD Source: Eur Respir J 2002; 20: Suppl. 38, 620s Year: 2002
The bronchial expression of vanin in moderate to severe asthma Source: International Congress 2019 – Airway inflammation: pharmacological mechanisms and novel targets Year: 2019
How to stage airflow limitation (AL) in patients with stable COPD? Source: International Congress 2019 – Physiologic assessment of airway diseases Year: 2019
Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is safe and well tolerated in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
TGF-β1 type II receptor (TGF-βRII) expression in pulmonary arteries of patients with severe COPD Source: Eur Respir J 2005; 26: Suppl. 49, 96s Year: 2005
Effect of phosphodiesterase 4B inhibitor GSK256066 on leukocyte/endothelium interactions from chronic obstructive pulmonary disease: an in vitro study. Source: International Congress 2017 – Management of COPD Year: 2017
Sputum cell mRNA transcripts demonstrate alteration of endothelin metabolism in severe asthma and COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013